Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

12 results about "Minimum bactericidal concentration" patented technology

The minimum bactericidal concentration (MBC) is the lowest concentration of an antibacterial agent required to kill a particular bacterium. It can be determined from broth dilution minimum inhibitory concentration (MIC) tests by subculturing to agar plates that do not contain the test agent. The MBC is identified by determining the lowest concentration of antibacterial agent that reduces the viability of the initial bacterial inoculum by ≥99.9%. The MBC is complementary to the MIC; whereas the MIC test demonstrates the lowest level of antimicrobial agent that inhibits growth, the MBC demonstrates the lowest level of antimicrobial agent that results in microbial death. This means that even if a particular MIC shows inhibition, plating the bacteria onto agar might still result in organism proliferation because the antimicrobial did not cause death. Antibacterial agents are usually regarded as bactericidal if the MBC is no more than four times the MIC. Because the MBC test uses colony-forming units as a proxy measure of bacterial viability, it can be confounded by antibacterial agents which cause aggregation of bacterial cells. Examples of antibacterial agents which do this include flavonoids and peptides.

Application of Xinjiang medicine mulberry extract in preparation of medicine for treating or preventing periapical periodontitis

PendingCN121371004AAntibacterial agentsAntipyreticDisinfectantPeriapical disease
The invention relates to the technical field of medicines, and particularly discloses application of a Xinjiang medicine mulberry extract in preparation of a medicine for treating or preventing periapical periodontitis, which is technically characterized in that the Xinjiang medicine mulberry extract is found and proved to have a remarkable inhibition effect on periapical periodontitis key pathogenic bacterium enterococcus faecalis for the first time, the minimum inhibitory concentration (MIC) is 0.604 mg / mL, and the Xinjiang medicine mulberry extract has a remarkable inhibition effect on the periapical periodontitis key pathogenic bacterium enterococcus faecalis. The minimum bactericidal concentration (MBC) is 1.875 mg / mL, and a biological membrane can be effectively inhibited and removed; in-vivo experiments of a rat periapical periodontitis model prove that the extract can remarkably reduce the number of bacteria in root canals and relieve periapical bone destruction, the curative effect is equivalent to that of calcium hydroxide, and the extract is non-toxic to main organs and high in biocompatibility. The invention provides a new candidate and a clear technical scheme for developing an efficient and low-toxicity natural plant source root canal disinfectant.
Owner:FIRST AFFILIATED HOSPITAL OF XINJIANG MEDICAL UNIVERSITY

Antibacterial peptide and application thereof in preventing and treating dental plaque and gingival problems

The invention discloses an antibacterial peptide and application thereof in preventing and treating dental plaque and gingival problems, and belongs to the technical field of biology. According to the invention, two cationic antibacterial peptides LR18 and LR18-2 with amphiphilic alpha-helical structures are designed from the beginning. The two antibacterial peptides have good antibacterial and bactericidal activity on oral periodontal pathogenic bacteria (including fusobacterium nucleatum, porphyromonas gingivalis and streptococcus mutans), the minimum inhibitory concentration (MIC) is 62.5-500 [mu] g / mL, and the minimum bactericidal concentration (MBC) is 62.5-2000 [mu] g / mL. The structure is simple, the chemical synthesis difficulty is low, a high-purity product can be directly synthesized, the cell hemolytic activity is low, the safety is high, the product can be used for preparing oral antibacterial drugs and / or oral care products, and oral diseases are prevented and treated by inhibiting the growth of oral periodontal pathogenic bacteria.
Owner:SHANDONG UNIV +1

Application of glychalon A, medicine

PendingCN122272544ABiotechnologyChalcone
This application discloses the application and pharmaceutical properties of glycyrrhizin chalcone A, belonging to the field of biomedical technology. The technical solution is as follows: the application of glycyrrhizin chalcone A in the preparation of anti-MS drugs. In the case that the prior art clearly shows that glycyrrhizin chalcone A has no inhibitory ability against Gram-negative bacteria, this application unexpectedly discovered that it exhibits inhibitory ability against mycoplasma, which belongs to the same genus of Gram-negative bacteria. Furthermore, the in vitro experiments of this application demonstrate that LCA has low minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) against MS standard strains and clinical isolates, and has good activity.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY

An antimicrobial peptide and its use in the preparation of products for the prevention and / or treatment of oral diseases

The application belongs to the technical field of biological medicine, and particularly relates to an antimicrobial peptide and application thereof in preparation of products for preventing and / or treating oral diseases. The amino acid sequence of the antimicrobial peptide Perceptide-302 is shown as SEQ ID NO. 1. Experimental results of the application show that the polypeptide can effectively inhibit and kill oral pathogenic bacteria at a low concentration, the minimum inhibitory concentration (MIC) of the polypeptide on six kinds of bacteria, including Streptococcus mutans, Streptococcus sobrinus, Streptococcus sanguis, Streptococcus gordonii, Lactobacillus casei and Lactobacillus acidophilus, is 2.5 μg / mL-5 μg / mL, the minimum bactericidal concentration (MBC) is 5 μg / mL-10 μg / mL, and mechanism research is carried out on the most important clinical Streptococcus mutans. The application provides a new active ingredient and technical approach for developing a new type, efficient and safe oral disease prevention and treatment drug and product.
Owner:XIAN FEDERAL ORAL MEDICAL TECH CO LTD

SP-1 polypeptide and application of encoding gene thereof in inhibition of tight reaction and antibiosis

The invention provides an SP-1 polypeptide and application of a coding gene of the SP-1 polypeptide in inhibition of tight reaction and antibiosis, and belongs to the technical field of polypeptides. The amino acid sequence of the spider-derived SP-1 polypeptide is as shown in SEQ ID NO: 1. According to the present invention, the SP-1 polypeptide can specifically inhibit Escherichia coli and pseudomonas aeruginosa tight reaction key small molecule (p) ppGpp synthase activity, strong antibacterial activity is represented, and the MIC of the SP-1 polypeptide on Escherichia coli and pseudomonas aeruginosa is 2.4 [mu] M and 1.5 [mu] M respectively, and is significantly lower than the MIC (14.5 [mu] M and 12.3 [mu] M) of kanamycin of a positive control group under the same experiment condition; in addition, the SP-I peptide shows efficient bactericidal activity, the minimum bactericidal concentration of the SP-I peptide to escherichia coli and pseudomonas aeruginosa is 2.0 mu M, and the SP-I peptide can effectively inhibit generation of escherichia coli and pseudomonas aeruginosa biological membranes. Therefore, the SP-1 polypeptide can be used as an active ingredient to be applied to preparation of antibacterial drugs for inhibiting multidrug resistance bacteria.
Owner:GUANGDONG LABORATORY OF SOUTHERN OCEAN SCIENCE AND ENGINEERING (GUANGZHOU)

Application of naphthoquinone derivative in preparation of anti-helicobacter pylori medicine

The invention relates to an application of a naphthoquinone derivative in preparation of anti-helicobacter pylori drugs. The compound is 2-amino-3-chloro-1, 4-naphthoquinone (ACNQ) and shows strong inhibitory activity on standard strains of helicobacter pylori and various clinically separated drug-resistant strains, the minimum inhibitory concentration range of the compound is 0.0625-0.25 mu g / mL, and the compound is not prone to inducing generation of bacterial drug resistance. The minimum bactericidal concentration of ACNQ is 0.125 mu g / mL, and the bactericidal rate reaches 99.99% within 24 hours; under different pH culture conditions, the sterilization rate of the ACNQ with the concentration of 0.25 mu g / mL can reach 99.99% within 4 hours. In-vitro cytotoxicity experiments and in-vivo safety evaluation of mice both prove that the compound has low toxicity in an effective concentration range. The ACNQ provides a new choice for developing novel anti-helicobacter pylori drugs, especially drugs for drug-resistant strain infection.
Owner:YOUJIANG MEDICAL UNIV FOR NATIONALITIES

Antibacterial composition, antibacterial nano-emulsion, antibacterial preparation and application of antibacterial composition, antibacterial nano-emulsion and antibacterial preparation

PendingCN120983409AAntibacterial agentsAmine active ingredientsBiotechnologyMulti resistant bacteria
The invention belongs to the technical field of preparation of antibacterial preparations, and particularly relates to an antibacterial composition, an antibacterial nano-emulsion, an antibacterial preparation and application of the antibacterial composition, the antibacterial nano-emulsion and the antibacterial preparation. Through verification, the benzalkonium bromide and the chlorhexidine acetate can achieve the effect of synergistically resisting methicillin-resistant staphylococcus aureus (MRSA) by inhibiting or removing a biological membrane (cell membrane), and particularly, the nano-emulsion prepared from the benzalkonium bromide and the chlorhexidine acetate has an excellent MRSA resisting effect; the minimum inhibitory concentration (MIC) of the prepared nanoemulsion on MRSA bacteria is 1.5625 [mu] g / mL, and the minimum bactericidal concentration (MBC) of the prepared nanoemulsion on MRSA bacteria is 6.25 [mu] g / mL; in addition, the prepared nanoemulsion is low in toxicity and excellent in stability. Moreover, the antibacterial preparation disclosed by the invention is simple in preparation process, stable in quality and suitable for large-scale production, can be widely applied to infection of multiple drug-resistant bacteria of skin wounds, and has a good market application prospect.
Owner:ARMY MEDICAL UNIV

Application of 2-nitrophenol sodium salt in inhibition of aspergillus flavus growth and toxin synthesis

The invention discloses an application of a plant growth regulator 2-nitrophenol sodium salt in inhibition of aspergillus flavus growth and toxin synthesis, which can effectively inhibit spore germination and mycelial growth of aspergillus flavus, and has a minimum inhibitory concentration of 100 [mu] g / mL and a minimum bactericidal concentration of 200 [mu] g / mL. The invention further shows that the compound can destroy the integrity of the cell membrane of aspergillus flavus and the ultrastructure of the cell of aspergillus flavus, induce the accumulation of a large amount of active oxygen in the cell, and trigger the damage of mitochondrial function and energy metabolism disorder, thereby inhibiting the growth and toxin production of fungi. When the compound is added into feed, the growth of aspergillus flavus can be effectively inhibited, and the pollution of aspergillus flavus and aflatoxin can be remarkably reduced. Under the effective inhibitory concentration, the 2-nitrophenol sodium salt does not show obvious toxicity to HeLa cells, and has application safety. The invention provides a novel application and a technical scheme for developing a novel safe and efficient green prevention and control technology for preventing and controlling aspergillus flavus and toxin pollution thereof.
Owner:ZHONGKAI UNIV OF AGRI & ENG

ANTIBACTERIAL GEL FROM THE ACTIVE INGREDIENT OF PISTACHIO SHELL EXTRACT

PendingIDS00202607833ABiotechnologyBenzoic acid
This invention relates to a gel preparation with pistachio shell extract as the active ingredient which has the effect of inhibiting Staphylococcus aureus bacteria. The gel consists of pistachio shell extract made from a maceration process using 70% alcohol, 5% CMC-Na gel base, 5.0% glycerin humectant, 3.0% propylene glycol, 0.25% methyl paraben preservative and aquades solvent added up to 100%. The gel has antibacterial activity which is characterized by the formation of an inhibition zone against Staphylococcus aureus bacteria. The emergence of this inhibition zone is due to the active compound contained in the gel base diffusing through the media so that it is able to inhibit the growth of Staphylococcus aureus bacteria. The positive control used in this antibacterial test is 1.2% clindamycin phosphate gel.From the results of the antibacterial effectiveness test that has been carried out, it was found that 10% to 25% pistachio shell extract gel can inhibit ≥15mm-24mm of Staphylococcus aureus bacterial growth with Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) values ​​of 80% and 100%, respectively.
Owner:HEKA MARETA NUGRAHENI +1

Application of gossypol in preparation of medicine for preventing and treating chicken necrotic enteritis

The invention relates to application of gossypol in preparation of a medicine for treating chicken necrotic enteritis, and belongs to the field of medicine. In-vitro antibacterial activity tests, hemolytic activity inhibition tests, biofilm formation inhibition tests and chicken necrotic enteritis model tests prove that gossypol has a prevention and treatment effect on chicken necrotic enteritis caused by clostridium perfringens infection. The gossypol is preferably gossypol acetate, the minimum inhibitory concentration of the gossypol acetate to clostridium perfringens is 16 mu g / mL, and the minimum bactericidal concentration of the gossypol acetate to clostridium perfringens is 32 mu g / mL. It is found for the first time that gossypol can play a dual anti-infection role by inhibiting the hemolytic activity and biofilm formation of clostridium perfringens. The gossypol provided by the invention can effectively inhibit the growth of clostridium perfringens and the expression of virulence factors of the clostridium perfringens, meanwhile, the intestinal injury and growth performance of sick chickens are improved, and a new technical scheme is provided for green prevention and control of chicken necrotic enteritis.
Owner:湖南九安禾生物科技有限公司

Liquorice flower effective part extract as well as extraction method and application thereof

The invention discloses a liquorice flower effective part extract as well as an extraction method and application thereof. The effective part extract is prepared by the following steps: extracting liquorice flowers by using an alcohol / water solution, sequentially extracting by using petroleum ether and ethyl acetate, concentrating to obtain an ethyl acetate extract, dissolving the ethyl acetate extract by using methanol, decolorizing, removing impurities, concentrating and drying to obtain the effective part extract. The licorice flower effective part extract extracted by petroleum ether and ethyl acetate has the advantages of oxidation resistance (the IC50 values of DPPH free radicals and ABTS free radicals are respectively 33.25 mu g / mL and 1t), and the IC50 values of DPPH free radicals and ABTS free radicals are respectively 33.25 mu g / mL and 1t; the compound disclosed by the invention has the advantages of good anti-tumor activity (the minimum inhibitory concentration range for escherichia coli and staphylococcus aureus is 0.07-0.62 mg / mL and the minimum bactericidal concentration range for escherichia coli and staphylococcus aureus is 0.15-2.5 mg / mL), good anti-tumor activity and potential application value in the fields of anti-oxidation, anti-bacterial, anti-cancer medicines and the like.
Owner:NINGXIA MEDICAL UNIV +1

Pth-St1 antibacterial derived peptide and application thereof

The invention discloses a Pth-St1 antibacterial derived peptide and application thereof, and belongs to the field of application of peptide antibiotics. The amino acid residue sequence of the antibacterial derived peptide (Design1867) is as follows: RKLVRQLHRFKGKLVRKLH. The invention further discloses a preparation method of the antibacterial derived peptide (Design1867). The derivative peptide provided by the invention has a stronger bactericidal effect, and the minimum bactericidal concentrations of the derivative peptide to escherichia coli and pectobacterium soft rot reach 250 mu g / mL and 62.5 mu g / mL respectively; meanwhile, the safety of the Design1867 polypeptide is also proved, so that the Design1867 polypeptide is expected to become a novel prevention and control product and means for pectobacterium soft rot.
Owner:NINGBO UNIV